Galderma Group AG (GALD)

Currency in CHF
162.10
+0.30(+0.19%)
Closed·
GALD is included in our AI-picked strategies. See how they work
Fair Value
Day's Range
160.50162.80
52 wk Range
72.70170.10
Key Statistics
Bid/Ask
161.50 / 163.80
Prev. Close
161.8
Open
161
Day's Range
160.5-162.8
52 wk Range
72.7-170.1
Volume
154.39K
Average Volume (3m)
740.22K
1-Year Change
61.16%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
GALD Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
158.16
Downside
-2.43%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a high earnings multiple

Galderma Group AG News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Galderma Group AG Company Profile

Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes ACTINICA, Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, Mirvaso, NEMLUVIO, Relfydess, Benzac, Loceryl, and TRI-LUMA in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.

Galderma Group AG Earnings Call Summary for Q3/2025

  • Galderma reports 21% YoY growth in Q3 2025, raises full-year net sales growth guidance to 17.0-17.7%
  • Record net sales of $3.7 billion for first nine months of 2025, 15% increase YoY
  • Core EBITDA margin guidance adjusted to 23.1-23.6%, stock rises 2.86% post-announcement
  • $650 million investment to expand U.S. manufacturing footprint, strong growth in Asia and Latin America
  • CEO highlights low dropout rates for Nimluvio, expresses confidence in portfolio and innovation strategy
Last Updated: 2025-10-23, 10:58 a/m
Read Full Transcript

Compare GALD to Peers and Sector

Metrics to compare
GALD
Peers
Sector
Relationship
P/E Ratio
128.9x25.1x−0.6x
PEG Ratio
0.050.170.00
Price/Book
6.3x4.8x2.6x
Price / LTM Sales
10.4x4.7x3.2x
Upside (Analyst Target)
0.9%5.4%42.7%
Fair Value Upside
Unlock1.8%6.4%Unlock

Analyst Ratings

9 Buy
3 Hold
1 Sell
Ratings:
13 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 158.16
(-2.43% Downside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
UBS
Buy190.00+17.21%138.00UpgradeNov 26, 2025
UBS
Buy190.00+17.21%138.00UpgradeNov 25, 2025
RBC Capital
Hold140.00-13.63%128.00MaintainOct 29, 2025
Kepler Cheuvreux
Buy167.00+3.02%165.00MaintainOct 28, 2025
Barclays
Buy155.00-4.38%140.00MaintainOct 28, 2025

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 1.59%
Dividend Yield
0.09%
Industry Median 2.39%
Annualized payout
0.15
Paid unevenly
5-Years Growth
-
Growth Streak

Earnings

Latest Release
Jul 24, 2025
EPS / Forecast
0.82 / --
Revenue / Forecast
2.47B / 1.098B
EPS Revisions
Last 90 days

GALD Income Statement

People Also Watch

57.84
SDZ
+0.24%
35.7500
GASI
+0.51%
61.55
ACLN
0.00%
92.800
NEKG
+0.05%
29.120
NDXG
+0.48%

FAQ

What Is the Galderma (GALD) Stock Price Today?

The Galderma stock price today is 162.10

What Stock Exchange Does Galderma Trade On?

Galderma is listed and trades on the Switzerland Stock Exchange stock exchange.

What Is the Stock Symbol for Galderma?

The stock symbol for Galderma is "GALD."

Does Galderma Pay Dividends? What’s The Current Dividend Yield?

The Galderma dividend yield is 0.09%.

What Is the Galderma Market Cap?

As of today, Galderma market cap is 38.41B.

What Is Galderma's Earnings Per Share (TTM)?

The Galderma EPS (TTM) is 1.59.

From a Technical Analysis Perspective, Is GALD a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Galderma Stock Split?

Galderma has split 0 times.

What is the current trading status of Galderma (GALD)?

As of Dec 31, 2025, Galderma (GALD) is trading at a price of 162.10, with a previous close of 161.80. The stock has fluctuated within a day range of 160.50 to 162.80, while its 52-week range spans from 72.70 to 170.10.

What Is Galderma (GALD) Price Target According to Analysts?

The average 12-month price target for Galderma is CHF158.15929664, with a high estimate of CHF188.2920675 and a low estimate of CHF108.19429112. 9 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an -2.43% Downside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.